Ixekizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ixekizumab comprises 105 peer-reviewed publications across 15 journals, 29 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Arthritis, Psoriatic, Psoriasis, Spondylarthritis, and Axial Spondyloarthritis. Most recent publication: Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging., Rheumatol Ther, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).
    Callis Duffin K, Bagel J, Bukhalo M, et al. · J Eur Acad Dermatol Venereol · 2017
    PubMed: PMID 27500949 · NCT01777191 (UNCOVER-A)
  2. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
    Ramanan AV, Ruperto N, Foeldvari I, et al. · Lancet Rheumatol · 2026
    PubMed: PMID 41785908 · NCT04527380 · Arthritis, Juvenile
  3. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS, Seyger MMB, Magariños GA, et al. · JAMA Dermatol · 2022
    PubMed: PMID 35416908 · NCT03073200 (Ixora-peds)
  4. External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab.
    Ortolan A, Ramiro S, Ramonda R, et al. · Rheumatology (Oxford) · 2023
    PubMed: PMID 36282526 · NCT02696785 (COAST-V) · Spondylarthritis
  5. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol · 2026
    PubMed: PMID 41903163 · NCT06588296 (TOGETHER-PsA) · Arthritis, Psoriatic
  6. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
    Maksymowych WP, Lambert RGW, Bolce RJ, et al. · Lancet Rheumatol · 2025
    PubMed: PMID 39983751 · NCT02696785 (COAST-V) · Spondylarthritis
  7. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP, Bolce R, Gallo G, et al. · Rheumatology (Oxford) · 2022
    PubMed: PMID 35188180 · NCT02696785 (COAST-V) · Spondylarthritis
  8. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP, Baraliakos X, Lambert RG, et al. · Lancet Rheumatol · 2024
    PubMed: PMID 38288892 · NCT02757352 (COAST-X) · Axial Spondyloarthritis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01474512
UNCOVER-1
PsoriasisPercentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)
Week 12
Ixe Q2W89.1 percentage of participants
Ixe Q4W82.6 percentage of participants
Placebo3.9 percentage of participants
NCT01474512
UNCOVER-1
PsoriasisPercentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
Week 12
Ixe Q2W81.8 percentage of participants
Ixe Q4W76.4 percentage of participants
Placebo3.2 percentage of participants
NCT01597245
UNCOVER-2
PsoriasisPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
Week 12
50 mg ETN - Induction Period41.6 percentage of participants
Ixe Q2W - Induction Period89.7 percentage of participants
Ixe Q4W - Induction Period77.5 percentage of participants
Placebo - Induction Period2.4 percentage of participants
NCT01597245
UNCOVER-2
PsoriasisPercentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
Week 12
50 mg Etanercept (ETN) - Induction Period36.0 percentage of participants
Ixe Q2W - Induction Period83.2 percentage of participants
Ixe Q4W - Induction Period72.9 percentage of participants
Placebo - Induction Period2.4 percentage of participants
NCT01624233
UNCOVER-J
PsoriasisPercentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)
Week (Wk) 12
80 mg Ixekizumab (LY2439821)98.7 percentage of participants
NCT01646177
UNCOVER-3
PsoriasisNumber of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)
Week 12
50 mg Etanercept159 Participants
80 mg Ixekizumab Dosing Regimen 1 (Q2W)310 Participants
80 mg Ixekizumab Dosing Regimen 2 (Q4W)291 Participants
Placebo13 Participants
NCT01646177
UNCOVER-3
PsoriasisNumber of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
Week 12
50 mg Etanercept204 Participants
80 mg Ixekizumab Dosing Regimen 1 (Q2W)336 Participants
80 mg Ixekizumab Dosing Regimen 2 (Q4W)325 Participants
Placebo14 Participants
NCT01695239
SPIRIT-P1
Arthritis, PsoriaticPercentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20])
Week 24
Adalimumab Q2W57.4 percentage of participants
Ixekizumab Q2W62.1 percentage of participants
Ixekizumab Q4W57.9 percentage of participants
Placebo30.2 percentage of participants
NCT01777191
UNCOVER-A
—Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
80 mg Ixekizumab Auto-Injector14.8 micrograms/milliliter (µg/mL)
80 mg Ixekizumab Prefilled Syringe15.0 micrograms/milliliter (µg/mL)
NCT01777191
UNCOVER-A
—PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
80 mg Ixekizumab Auto-Injector154 micrograms*day/milliliter (µg*day/mL)
80 mg Ixekizumab Prefilled Syringe157 micrograms*day/milliliter (µg*day/mL)
NCT02349295
SPIRIT-P2
Arthritis, PsoriaticPercentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)
Week 24
Ixekizumab 80 mg Q2W48.0 Percentage of Participants
Ixekizumab 80 mg Q4W53.3 Percentage of Participants
Placebo19.5 Percentage of Participants
NCT02387801PsoriasisTime to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score
Baseline through Week 12
Ixekizumab Q2W5.0 Days
Ixekizumab Q4W6.0 Days
NCT02513550
IXORA-P
—Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Week 52
80 mg Ixekizumab Q2W85.9 Percentage of participants
80 mg Ixekizumab Q4W79 Percentage of participants
80 mg Ixekizumab Q4W/Q2W83.7 Percentage of participants
NCT02513550
IXORA-P
—Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)
Week 52
80 mg Ixekizumab Q2W78.6 Percentage of participants
80 mg Ixekizumab Q4W70.6 Percentage of participants
80 mg Ixekizumab Q4W/Q2W72.5 Percentage of participants
NCT02561806
IXORA-S
—Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
Week 12
Ixekizumab72.8 percentage of participants
Ustekinumab42.2 percentage of participants
NCT02584855
SPIRIT P3
Arthritis, PsoriaticDouble-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA])
Double Blind Randomization through Week 104 (or Early Termination or Relapse)
IxekizumabNA Weeks
Placebo22.29 Weeks
NCT02634801—Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24
Week 24
Fumaric Acid Esters22.2 Percentage of Participants
Ixekizumab90.7 Percentage of Participants
Methotrexate70.4 Percentage of Participants
NCT02696785
COAST-V
SpondylarthritisPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
Week 16
Adalimumab35.6 percentage of participants
IXE80Q2W51.8 percentage of participants
IXE80Q4W48.1 percentage of participants
Placebo18.4 percentage of participants
NCT02696798
COAST-W
SpondylarthritisPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
Week 16
80 mg Q2W Ixekizumab30.6 Percentage of participants
80 mg Q4W Ixekizumab25.4 Percentage of participants
Placebo12.5 Percentage of participants
NCT02718898
IXORA-Q
PsoriasisNumber of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)
Week 12
Ixekizumab 80mg Q2W55 Participants
Placebo6 Participants
NCT02757352
COAST-X
Axial SpondyloarthritisPercentage of Participants Achieving an ASAS40 Response
Week 52
Ixekizumab 80 mg Q2W31.4 percentage of participants
Ixekizumab 80 mg Q4W30.2 percentage of participants
Placebo13.3 percentage of participants
NCT02757352
COAST-X
Axial SpondyloarthritisPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
Week 16
Ixekizumab 80 mg Q2W40.2 percentage of participants
Ixekizumab 80 mg Q4W35.4 percentage of participants
Placebo19.0 percentage of participants
NCT03073200
Ixora-peds
—Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)
Week 12
Ixekizumab88.7 percentage of participants
Placebo25 percentage of participants
NCT03073200
Ixora-peds
—Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)
Week 12
Ixekizumab80.9 percentage of participants
Placebo10.7 percentage of participants
NCT03129100Axial SpondyloarthritisPercentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)
Week 64
Combined IXE83.3 Percentage of participants
Placebo54.7 Percentage of participants
NCT03364309Skin DiseasesPercentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Week 12
Ixekizumab 80mg Q2W93.8 Percentage of participants
Ixekizumab 80mg Q4W87.4 Percentage of participants
Placebo8.0 Percentage of participants
NCT03364309Skin DiseasesPercentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
Week 12
Ixekizumab 80mg Q2W86.4 Percentage of participants
Ixekizumab 80mg Q4W79.9 Percentage of participants
Placebo3.4 Percentage of participants
NCT04285229SpondylarthritisPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants
Week 16
Ixekizumab 80mg Q4W40.9 Percentage of Participants
Placebo7.8 Percentage of Participants
NCT04527380Arthritis, JuvenilePercentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
Week 16
Ixekizumab - OLT Period88.9 Percentage of participants

Publications by year

2005–2026: 105 publications.

2005
1
2007
1
2012
3
2015
2
2016
5
2017
6
2018
2
2019
4
2020
9
2021
20
2022
16
2023
7
2024
15
2025
10
2026
4

Publications by indication

Arthritis, Psoriatic (39)

  • Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Arthritis Rheumatol · 2026 · PMID 41903163 · NCT06588296
  • Filling the "GAP" in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint.
    Rheumatol Ther · 2025 · PMID 38955921 · NCT01695239
  • Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials.
    Rheumatol Ther · 2025 · PMID 40014255 · NCT01695239
  • Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.
    BMC Rheumatol · 2025 · PMID 30886974 · NCT01695239
  • Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act.
    Ann Rheum Dis · 2025 · PMID 40090785 · NCT07443956

Psoriasis (27)

  • Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
    Dermatol Ther (Heidelb) · 2024 · PMID 38647975 · NCT01646177
  • Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Dermatol Ther (Heidelb) · 2024 · PMID 38521874 · NCT01597245
  • Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.
    Adv Ther · 2023 · PMID 37356077 · NCT03073213
  • A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Rheumatol Ther · 2023 · PMID 37400681 · NCT01597245
  • First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Ann Surg · 2023 · PMID 35129472 · NCT07352566

Spondylarthritis (17)

  • Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging.
    Rheumatol Ther · 2026 · PMID 41495585 · NCT04285229
  • Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.
    Rheumatol Ther · 2026 · PMID 41417207 · NCT02696798
  • The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
    Lancet Rheumatol · 2025 · PMID 39983751 · NCT02696785
  • Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level.
    Rheumatol Ther · 2025 · PMID 40343690 · NCT04285229
  • Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis.
    Rheumatol Ther · 2024 · PMID 38907104 · NCT04285229

Axial Spondyloarthritis (8)

  • Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.
    Adv Ther · 2025 · PMID 40694276 · NCT02757352
  • Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Lancet Rheumatol · 2024 · PMID 38288892 · NCT02757352
  • Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks.
    BMC Rheumatol · 2024 · PMID 34560906 · NCT02757352
  • Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
    Arthritis Care Res (Hoboken) · 2022 · PMID 33044756 · NCT02757352
  • Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    Adv Ther · 2022 · PMID 35429281 · NCT02757352

Skin Diseases (2)

  • Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.
    Adv Ther · 2025 · PMID 39347926 · NCT03364309
  • Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.
    Adv Ther · 2025 · PMID 39535685 · NCT03364309

Diabetes Mellitus, Type 1 (1)

  • Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes.
    BMJ Open · 2025 · PMID 41224288 · NCT04589325

Publications by journal

Trial-results highlights

In studies of moderate to severe plaque psoriasis, treatment with Ixekizumab showed specific outcomes at Week 12. In NCT01474512, the percentage of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI75) was 89.1% for the Ixe Q2W arm and 82.6% for the Ixe Q4W arm, compared to 3.9% for placebo. For the Static Physician Global Assessment (sPGA) of 0 or 1, 81.8% of participants in the Ixe Q2W arm and 76.4% in the Ixe Q4W arm achieved this outcome, versus 3.2% for placebo. Similarly, in NCT01597245, PASI75 was achieved by 89.7% of participants in the Ixe Q2W arm and 77.5% in the Ixe Q4W arm, compared to 41.6% for the 50 mg Etanercept arm and 2.4% for placebo. For sPGA of 0 or 1, 83.2% of participants in the Ixe Q2W arm and 72.9% in the Ixe Q4W arm achieved this, compared to 36.0% for the 50 mg Etanercept arm and 2.4% for placebo. In NCT01624233, 98.7% of participants in the 80 mg Ixekizumab arm achieved PASI75 at Week 12.

Another study for moderate to severe chronic plaque psoriasis, NCT01646177, reported participant counts at Week 12. For achieving a Static Physician Global Assessment (sPGA) of 0 or 1, 310 participants in the 80 mg Ixekizumab Dosing Regimen 1 (Q2W) arm and 291 participants in the 80 mg Ixekizumab Dosing Regimen 2 (Q4W) arm achieved this outcome, compared to 159 participants in the 50 mg Etanercept arm and 13 participants in the placebo arm. For achieving Psoriasis Area and Severity Index (PASI) ≥75% improvement, 336 participants in the 80 mg Ixekizumab Dosing Regimen 1 (Q2W) arm and 325 participants in the 80 mg Ixekizumab Dosing Regimen 2 (Q4W) arm achieved this, compared to 204 participants in the 50 mg Etanercept arm and 14 participants in the placebo arm.

For active psoriatic arthritis, the NCT01695239 (SPIRIT-P1) study evaluated the percentage of participants achieving an American College of Rheumatology 20 (ACR20) response at Week 24. In this study, 62.1% of participants in the Ixekizumab Q2W arm and 57.9% in the Ixekizumab Q4W arm achieved an ACR20 response. This compared to 57.4% in the Adalimumab Q2W arm and 30.2% in the placebo arm.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Ixekizumab publications (105)

2026 (4 papers)

  1. Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging.
    Zhu X, Hu J, Liu D, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41495585 · NCT04285229 · Spondylarthritis
  2. Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.
    Reveille JD, Rudwaleit M, Rahman P, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41417207 · NCT02696798 (COAST-W) · Spondylarthritis
  3. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
    Ramanan AV, Ruperto N, Foeldvari I, et al. · Lancet Rheumatol · 2026 · Derived
    PubMed: PMID 41785908 · NCT04527380 · Arthritis, Juvenile
  4. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol · 2026 · Derived
    PubMed: PMID 41903163 · NCT06588296 (TOGETHER-PsA) · Arthritis, Psoriatic

2025 (10 papers)

  1. Filling the "GAP" in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint.
    Tillett W, Birt J, Vadhariya A, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 38955921 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  2. Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes.
    Seyed Ahmadi S, Korsgren O, Jansson PA, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 41224288 · NCT04589325 (I-DIT) · Diabetes Mellitus, Type 1
  3. Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.
    Navarro-Compán V, Reveille JD, Rahman P, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40694276 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  4. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
    Maksymowych WP, Lambert RGW, Bolce RJ, et al. · Lancet Rheumatol · 2025 · Derived
    PubMed: PMID 39983751 · NCT02696785 (COAST-V) · Spondylarthritis
  5. Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.
    Li X, Ding Y, Zhang C, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 39347926 · NCT03364309 · Skin Diseases
  6. Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials.
    Kristensen LE, McGonagle D, Rudwaleit M, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 40014255 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  7. Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level.
    Kong N, Hu J, Liu D, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 40343690 · NCT04285229 · Spondylarthritis
  8. Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.
    Gao X, Pan W, Zheng M, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 39535685 · NCT03364309 · Skin Diseases
  9. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.
    Coates LC, Orbai AM, Morita A, et al. · BMC Rheumatol · 2025 · Derived
    PubMed: PMID 30886974 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  10. Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act.
    Sattar N, Sattar LJ, McInnes IB, et al. · Ann Rheum Dis · 2025 · Background
    PubMed: PMID 40090785 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2024 (15 papers)

  1. Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis.
    Zhu X, Hu J, Liu D, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38907104 · NCT04285229 · Spondylarthritis
  2. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
    Xue Y, Hu J, Liu D, et al. · BioDrugs · 2024 · Derived
    PubMed: PMID 37737952 · NCT04285229 · Spondylarthritis
  3. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.
    Tillett W, Lin CY, Zbrozek A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31154634 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  4. Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.
    Ramiro S, Lukas C, Nissen MJ, et al. · Semin Arthritis Rheum · 2024 · Derived
    PubMed: PMID 39509838 · NCT02696785 (COAST-V) · Spondylarthritis
  5. Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.
    Ramiro S, Lukas C, Bessette L, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 39004432 · NCT02696785 (COAST-V) · Spondylarthritis
  6. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
    Mease P, Walsh JA, Baraliakos X, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31254223 · NCT02696785 (COAST-V) · Spondylarthritis
  7. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP, Baraliakos X, Lambert RG, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38288892 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  8. Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
    Kameda H, Hagimori K, Morisaki Y, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37858007 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  9. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
    Gooderham M, Vender R, Crowley J, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38332436 · NCT03573323 (IXORA-R)
  10. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
    Egeberg A, Hawkes JE, Somani N, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38647975 · NCT01646177 (UNCOVER-3) · Psoriasis
  11. Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks.
    Deodhar A, Mease P, Marzo-Ortega H, et al. · BMC Rheumatol · 2024 · Derived
    PubMed: PMID 34560906 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  12. Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial.
    de Vlam K, Maksymowych WP, Gallo G, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38637464 · NCT02696785 (COAST-V) · Spondylarthritis
  13. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
    Armstrong AW, Jaleel T, Merola JF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38814433 · NCT02349295 (SPIRIT-P2) · Arthritis, Psoriatic
  14. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Armstrong A, González-Cantero A, Khattri S, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38521874 · NCT01597245 (UNCOVER-2) · Psoriasis
  15. Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study.
    Ishchenko A, Pazmino S, Neerinckx B, et al. · Arthritis Care Res (Hoboken) · 2024 · Background
    PubMed: PMID 37667975 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2023 (7 papers)

  1. Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.
    Zheng M, Chen X, Wang F, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37356077 · NCT03073213 · Psoriasis
  2. External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab.
    Ortolan A, Ramiro S, Ramonda R, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36282526 · NCT02696785 (COAST-V) · Spondylarthritis
  3. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Kirkham BW, Egeberg A, Behrens F, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37400681 · NCT01597245 (UNCOVER-2) · Psoriasis
  4. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.
    Deodhar A, Poddubnyy D, Rahman P, et al. · J Rheumatol · 2023 · Derived
    PubMed: PMID 36792107 · NCT02696785 (COAST-V) · Spondylarthritis
  5. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  6. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis
  7. Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center.
    Li B, Huang H, Zhao J, et al. · Rheumatol Ther · 2023 · Background
    PubMed: PMID 36264448 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2022 (16 papers)

  1. Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
    Walsh JA, Magrey MN, Baraliakos X, et al. · Arthritis Care Res (Hoboken) · 2022 · Derived
    PubMed: PMID 33044756 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  2. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE, de Vlam K, Walsh JA, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35429281 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  3. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D, Østergaard M, Reveille JD, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 34853086 · NCT02696798 (COAST-W) · Spondylarthritis
  4. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS, Seyger MMB, Magariños GA, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 35416908 · NCT03073200 (Ixora-peds)
  5. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
    Morita A, Okubo Y, Morisaki Y, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34967916 · NCT03942042 · Psoriasis
  6. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP, Bolce R, Gallo G, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 35188180 · NCT02696785 (COAST-V) · Spondylarthritis
  7. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE, Blauvelt A, Gallo G, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 35279805 · NCT01474512 (UNCOVER-1) · Psoriasis
  8. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials.
    Eder L, Tony HP, Odhav S, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35397092 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  9. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
    Deodhar AA, Combe B, Accioly AP, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35393269 · NCT02584855 (SPIRIT P3) · Arthritis, Psoriatic
  10. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.
    Coates LC, Smolen JS, Mease PJ, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 36171019 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  11. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
    Coates LC, Kishimoto M, Gottlieb A, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 29299340 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  12. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
    Chabra S, Gill BJ, Gallo G, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35449322 · NCT03848403
  13. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
    Braun J, Kiltz U, Deodhar A, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 35853675 · NCT03129100 · Axial Spondyloarthritis
  14. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  15. Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis.
    Loganathan A, Kamalaraj N, El-Haddad C, et al. · Int J Rheum Dis · 2022 · Background
    PubMed: PMID 34076348 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic
  16. Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study.
    Gok K, Nas K, Tekeoglu I, et al. · Rheumatol Int · 2022 · Background
    PubMed: PMID 34453579 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2021 (20 papers)

  1. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
    Wasel N, Thaçi D, French LE, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
    PubMed: PMID 32415575 · NCT02561806 (IXORA-S)
  2. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS, van den Reek JMPA, Grine L, et al. · Trials · 2021 · Derived
    PubMed: PMID 34656148 · NCT04340076 (BeNeBio) · Psoriasis
  3. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
    Smolen JS, Sebba A, Ruderman EM, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33200394 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  4. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
    Schweikert B, Malmberg C, Núñez M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32792421 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  5. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P, Goldblum O, Disch D, et al. · J Drugs Dermatol · 2021 · Derived
    PubMed: PMID 32845588 · NCT01597245 (UNCOVER-2) · Psoriasis
  6. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
    Reich K, Augustin M, Thaçi D, et al. · Br J Dermatol · 2021 · Derived
    PubMed: PMID 31376153 · NCT02634801
  7. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
    Orbai AM, Gratacós J, Turkiewicz A, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33278016 · NCT02349295 (SPIRIT-P2) · Arthritis, Psoriatic
  8. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
    Leonardi C, Reich K, Foley P, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
    PubMed: PMID 32200512 · NCT01597245 (UNCOVER-2) · Psoriasis
  9. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
    Haynes D, Strunck JL, Topham CA, et al. · JAMA Dermatol · 2021 · Derived
    PubMed: PMID 32293641 · NCT03485976 · Pityriasis Rubra Pilaris
  10. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
    Deodhar AA, Mease PJ, Rahman P, et al. · BMC Rheumatol · 2021 · Derived
    PubMed: PMID 34538257 · NCT02696785 (COAST-V) · Spondylarthritis
  11. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
    Deodhar A, Mease P, Rahman P, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33284423 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  12. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
    Combe B, Tsai TF, Huffstutter JE, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33499913 · NCT02349295 (SPIRIT-P2) · Arthritis, Psoriatic
  13. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
    Coates LC, Pillai SG, Tahir H, et al. · Arthritis Rheumatol · 2021 · Derived
    PubMed: PMID 33682378 · NCT02584855 (SPIRIT P3) · Arthritis, Psoriatic
  14. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V, van der Heijde D, Fleischmann RM, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 32031665 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  15. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A, Leonardi C, Elewski B, et al. · Br J Dermatol · 2021 · Derived
    PubMed: PMID 32880909 · NCT03573323 (IXORA-R)
  16. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
    Blauvelt A, Lebwohl MG, Mabuchi T, et al. · J Am Acad Dermatol · 2021 · Derived
    PubMed: PMID 33253833 · NCT01646177 (UNCOVER-3) · Psoriasis
  17. Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland.
    Vallejo-Yagüe E, Burkard T, Möller B, et al. · J Clin Med · 2021 · Background
    PubMed: PMID 34300360 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic
  18. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis.
    Gupta S, Syrimi Z, Hughes DM, et al. · Rheumatol Int · 2021 · Background
    PubMed: PMID 33423070 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic
  19. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis.
    Green A, Shaddick G, Charlton R, et al. · Br J Dermatol · 2021 · Background
    PubMed: PMID 31209855 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic
  20. Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity - a cross-sectional study.
    Ferguson LD, Linge J, Dahlqvist Leinhard O, et al. · Rheumatology (Oxford) · 2021 · Background
    PubMed: PMID 33147607 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2020 (9 papers)

  1. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G, Reich A, Steinhoff M, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 30465321 · NCT01597245 (UNCOVER-2) · Psoriasis
  2. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS, Mease P, Tahir H, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32660977 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  3. Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).
    Honma M, Cai Z, Burge R, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 32910360 · NCT01624233 (UNCOVER-J) · Psoriasis
  4. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD, Orbai AM, Klitz U, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 30696483 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  5. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M, Wei JC, Landewé R, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31685553 · NCT02696798 (COAST-W) · Spondylarthritis
  6. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A, van der Heijde D, Gensler LS, et al. · Lancet · 2020 · Derived
    PubMed: PMID 31813637 · NCT02757352 (COAST-X) · Axial Spondyloarthritis
  7. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
    Combe B, Rahman P, Kameda H, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31964419 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  8. Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.
    Khattri S, Goldblum O, Solotkin K, et al. · J Clin Aesthet Dermatol · 2020 · Background
    PubMed: PMID 29785237 · NCT02387801 · Psoriasis
  9. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.
    Ferguson LD, Siebert S, McInnes IB, et al. · Nat Rev Rheumatol · 2020 · Background
    PubMed: PMID 31292564 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2019 (4 papers)

  1. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D, Gladman DD, Kishimoto M, et al. · J Rheumatol · 2019 · Derived
    PubMed: PMID 29247148 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  2. Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.
    Reich K, Jackson K, Ball S, et al. · J Invest Dermatol · 2019 · Derived
    PubMed: PMID 29751001 · NCT01646177 (UNCOVER-3) · Psoriasis
  3. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC, Combe B, Kremer JM, et al. · Rheumatology (Oxford) · 2019 · Derived
    PubMed: PMID 30053162 · NCT02349295 (SPIRIT-P2) · Arthritis, Psoriatic
  4. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
    Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 30343531 · NCT02696798 (COAST-W) · Spondylarthritis

2018 (2 papers)

  1. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB, Strand V, Kishimoto M, et al. · Rheumatology (Oxford) · 2018 · Derived
    PubMed: PMID 29945203 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  2. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.
    Gomez EV, Bishop JL, Jackson K, et al. · BioDrugs · 2018 · Derived
    PubMed: PMID 29116597 · NCT02543918

2017 (6 papers)

  1. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).
    Callis Duffin K, Bagel J, Bukhalo M, et al. · J Eur Acad Dermatol Venereol · 2017 · Trial result
    PubMed: PMID 27500949 · NCT01777191 (UNCOVER-A)
  2. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P, Guenther L, Gottlieb AB, et al. · J Eur Acad Dermatol Venereol · 2017 · Derived
    PubMed: PMID 27910156 · NCT01646177 (UNCOVER-3) · Psoriasis
  3. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P, Kirkham B, Okada M, et al. · Lancet · 2017 · Derived
    PubMed: PMID 28551073 · NCT02349295 (SPIRIT-P2) · Arthritis, Psoriatic
  4. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ, van der Heijde D, Ritchlin CT, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27553214 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  5. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, et al. · Am J Clin Dermatol · 2017 · Derived
    PubMed: PMID 28074446 · NCT01597245 (UNCOVER-2) · Psoriasis
  6. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, et al. · JAMA Dermatol · 2017 · Derived
    PubMed: PMID 26953848 · NCT01646177 (UNCOVER-3) · Psoriasis

2016 (5 papers)

  1. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
    Saeki H, Nakagawa H, Ishii T, et al. · J Eur Acad Dermatol Venereol · 2016 · Derived
    PubMed: PMID 25355284 · NCT01624233 (UNCOVER-J) · Psoriasis
  2. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG, Rich P, Menter A, et al. · J Eur Acad Dermatol Venereol · 2016 · Derived
    PubMed: PMID 25693783 · NCT01107457 · Psoriasis
  3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB, Blauvelt A, Papp KA, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27299809 · NCT01646177 (UNCOVER-3) · Psoriasis
  4. Immunoexpression of Th17-related cytokines in oral lichen planus.
    Monteiro BV, Pereira Jdos S, Nonaka CF, et al. · Appl Immunohistochem Mol Morphol · 2016 · Background
    PubMed: PMID 25356945 · NCT05030415 · Lichen Planus
  5. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis

2015 (2 papers)

  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, et al. · Lancet · 2015 · Derived
    PubMed: PMID 26072109 · NCT01646177 (UNCOVER-3) · Psoriasis
  2. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB, Leonardi CL, Lebwohl M, et al. · J Am Acad Dermatol · 2015 · Derived
    PubMed: PMID 25242558 · NCT01107457 · Psoriasis

2012 (3 papers)

  1. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C, Matheson R, Zachariae C, et al. · N Engl J Med · 2012 · Derived
    PubMed: PMID 22455413 · NCT01107457 · Psoriasis
  2. Obesity and the risk of psoriatic arthritis: a population-based study.
    Love TJ, Zhu Y, Zhang Y, et al. · Ann Rheum Dis · 2012 · Background
    PubMed: PMID 22586165 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic
  3. Obesity and risk of incident psoriatic arthritis in US women.
    Li W, Han J, Qureshi AA, et al. · Ann Rheum Dis · 2012 · Background
    PubMed: PMID 22562978 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2007 (1 paper)

  1. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.
    Setty AR, Curhan G, Choi HK, et al. · Arch Intern Med · 2007 · Background
    PubMed: PMID 17698691 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

2005 (1 paper)

  1. Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
    Gladman DD, Antoni C, Mease P, et al. · Ann Rheum Dis · 2005 · Background
    PubMed: PMID 15708927 · NCT07443956 (COMBAT-PsA) · Arthritis, Psoriatic

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).